It’s kind of a quiet Monday, at least in the health policy world. Could be that it’s a holiday. It could be that our attention is focused on the horrific

ONCE AGAIN, you have a choice. You can read about the economics of obesity through analyst-driven think pieces that dive into frozen vegetable sales and the impact of Ozempic on

This journal article makes the case -- via analysis of claims data -- that patients almost never fill scripts for obesity medicines. The topline is that 10 of every 11

It’s kind of a slow day today, which has me thinking ahead to the J.P. Morgan Health Care conference in January. My thoughts are swirling around a couple of things:

Egg on my face: yesterday, I suggested that an ICER white paper, prepared for CMS as a part of the price-setting process for Eliquis and Xarelto, showed that those two

Hoo boy, there is a lot out there. I’m going to focus on the IRA for this edition, but there’s some obesity analysis worth talking about, too. I’ll save that

This Congressional Budget Office report on the Center for Medicare & Medicaid Innovation makes for fascinating reading. As background, CMMI was created as part of the Affordable Care Act, designed

There is so much going on in the drug-pricing world that the media can’t always track it all down, so -- as much as I respect all the journalism out

There are two ways to think about this report from I-MAK that calculated that just four medicines -- Humira, Rituxan, Avastin and Lantus -- made more than $150 billion in

The United States does not have a government-sanctioned group that makes determination of the value of a given drug (and it still won’t, even after the Inflation Reduction Act is